173 related articles for article (PubMed ID: 29698549)
1. Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Wick W; Winkler F
Cancer; 2018 Jul; 124(13):2674-2676. PubMed ID: 29698549
[No Abstract] [Full Text] [Related]
2. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
DeAngelis LM
J Clin Oncol; 2009 Dec; 27(35):5861-2. PubMed ID: 19901101
[No Abstract] [Full Text] [Related]
4. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
5. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
6. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological diagnosis of gliomas by genotype analysis].
Nakamura M; Shimada K; Nakase H; Konishi N
Brain Nerve; 2009 Jul; 61(7):773-80. PubMed ID: 19618854
[TBL] [Abstract][Full Text] [Related]
10. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Rinne ML; Wen PY
Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
[No Abstract] [Full Text] [Related]
11. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
[TBL] [Abstract][Full Text] [Related]
12. [Management of gliomas].
Lévy S; Chapet S; Mazeron JJ
Cancer Radiother; 2014 Oct; 18(5-6):461-7. PubMed ID: 25201633
[TBL] [Abstract][Full Text] [Related]
13. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Levin VA
Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
[No Abstract] [Full Text] [Related]
14. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
[TBL] [Abstract][Full Text] [Related]
16. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Schiff D
Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Collins VP; Ichimura K; Di Y; Pearson D; Chan R; Thompson LC; Gabe R; Brada M; Stenning SP;
Acta Neuropathol Commun; 2014 Jun; 2():68. PubMed ID: 24952577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
